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Abstract
Rationale Residual effects of hypnotics on driving perfor-
mance have been mainly determined in studies using a stan-
dardized driving test with healthy good sleepers. Responses to
effects may differ, however, between insomniacs and healthy
volunteers due to the underlying sleep disorder. In addition, a
majority of insomniacs uses hypnotics chronically resulting in
the development of tolerance to impairing effects. Impaired
driving performance in healthy volunteers may then be an
overestimation of the actual effects in insomniacs.
Objectives The present study aims to compare the residual
effects of zopiclone 7.5 mg on on-the-road driving perfor-
mance of 16 middle-aged insomniacs chronically using hyp-
notics (chronic users), 16 middle-aged insomniacs not or
infrequently using hypnotics (infrequent users), and 16
healthy, age matched, good sleepers (controls).
Methods The study was conducted according to a 3×2
double-blind, placebo controlled crossover design, with three
groups and two treatment conditions. Treatments were single
oral doses of zopiclone 7.5 mg and placebo administered at
bedtime (2330 hours). Between 10 and 11 h after administra-
tion subjects performed a standardized highway driving test.
Results Zopiclone 7.5 mg significantly impaired on-the-road
driving performance in both insomnia groups and healthy
controls. The magnitude of impairment was significantly less
in the chronic users group as compared with the controls.
Conclusions The smaller magnitude of effects suggests that
investigating residual effects of hypnotics in healthy volun-
teers may yield a minor overestimation of the actual effects in
insomnia patients.
Keywords Zopiclone . Hypnotics . Residual effects .
Insomnia . On-the-road driving
Introduction
Residual daytime sedation is one of the main problems asso-
ciated with hypnotic drug use. Experimental studies have
demonstrated that the sedative actions of hypnotics impair
psychomotor and cognitive functioning the morning after
evening administration (Vermeeren 2004). The related re-
duced alertness and slowed reactions are a particular problem
for individuals who have to drive a car the morning following
an evening dose. Epidemiological studies have shown that use
of benzodiazepines, as well as zopiclone, is associated with an
increased risk of car accidents (Hemmelgarn et al. 1997;
Barbone et al. 1998; Neutel 1998; Glass et al. 2005).
The severity and duration of residual effects on actual
driving performance of hypnotics have been determined in
experimental studies using a standardized driving test
(Vermeeren 2004). Most of those studies have been conducted
in healthy, young volunteers rather than in the target popula-
tion, i.e., patients suffering from insomnia. Responses to the
residual effects of hypnotics, however, may differ between
insomnia patients and healthy good sleepers due to the under-
lying sleep disorder. In insomnia patients, hypnotics are ex-
pected to improve sleep and, as a consequence, they are
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expected to improve daytime performance as well. This im-
provement is supposed to attenuate or even compensate for
the impairing effects of hypnotics. Few studies have assessed
residual effects of hypnotics on on-the-road or simulated
driving in insomnia patients (Vermeeren 2004). They show
however that driving is also impaired in insomniacs. For
example, residual effects in women complaining of insomnia
have been found 10 h after administration of zopiclone 7.5 mg
(Volkerts et al. 1984) and lormetazepam 2 mg (Brookhuis
et al. 1994) in on-the-road driving. In addition, a study exam-
ining the effects of zopiclone 7.5 mg, zolpidem 10 mg, and
lormetazepam 1 mg on simulated driving in insomniac pa-
tients showed that zopiclone and lormetazepam, but not
zolpidem, impaired driving between 9 and 11 h after admin-
istration (Staner et al. 2005).
A second reason why responses to the residual effects of
hypnotics may differ between insomnia patients and healthy
good sleepers is that the majority of insomnia patients use
hypnotics for prolonged periods (Curran et al. 2003). This
may result in the development of tolerance to the impairing
effects. Impaired driving performance found in healthy
medication-naïve volunteers may then be an overestimation
of the actual effects in insomnia patients.
Finally, most users of hypnotics are older (Drake et al.
2003; Glass et al. 2005). On the one hand, age is associated
with changes in pharmacokinetics and pharmacodynamics
which may increase patients’ vulnerability to impairing effects
of hypnotics (Glass et al. 2005; Bocca et al. 2011). In that case,
the effects found in studies with healthy young volunteers
may be an underestimation of the effects in the target popula-
tion of the drugs. On the other hand, driving experience
increases with age, which may have a protective effect. For
example, results from an on-the-road driving study in 18
healthy, older drivers (ages ranging between 56 to 73 years)
showed that the effects of a hypnotic did not increase with age
(Leufkens and Vermeeren 2009). If anything, the effects in
older drivers seemed to be less severe than in younger drivers,
but this needs to be replicated.
Although there already exists much insight about the resid-
ual effects of hypnotics on driving performance, a study
directly comparing the effects between insomnia patients,
chronic users of hypnotics, and healthy good sleepers has
never been conducted. Recently, an observational study ex-
plored driving performance between pharmacologically treat-
ed and untreated older insomnia patients and healthy, age-
matched, good sleepers (Leufkens et al. 2014; Ramaekers
2011). Results showed that performance was not significantly
different between insomnia patients and healthy controls. In
addition, there were no significant differences between insom-
nia patients who chronically used hypnotics and patients who
used hypnotics infrequently. A limitation of that study was,
however, that the chronic users group used a variety of hyp-
notic drugs most of which were not expected to produce
residual sedation at all. In addition, variability in dose and
half-life may have added to the absence of any performance
impairment. In order to determine whether residual effects of
hypnotics on driving performance are similar or reduced in
insomnia patients as compared to healthy volunteers, studies
need to be conducted with hypnotics that have been shown to
produce residual impairment in healthy volunteer studies,
such as zopiclone (Vermeeren et al. 1998, 2002a; Leufkens
et al. 2009; Leufkens and Vermeeren 2009). A recent analysis
of pooled data from four studies showed that the average
effect of zopiclone 7.5 mg is equivalent to that found for
alcohol in the same test when blood alcohol concentrations
range between 0.05 and 0.08 % (Leufkens and Vermeeren
2014).
Therefore, the present study aims to compare the residual
effects of the frequently prescribed hypnotic zopiclone 7.5 mg
on driving performance of 16 older insomnia patients who
chronically use hypnotics, 16 older insomnia patients who do




All subjects in the present study participated in a previous
study by Leufkens and Ramaekers (Leufkens et al. 2014;
Ramaekers 2011). They were asked upon completion of the
former study to continue their participation in the present
study. In the previous study, insomnia patients, in the age
range of 52 to 73 years, were initially recruited through a
network of local general practitioners in the region of Maas-
tricht, The Netherlands (Regionaal Netwerk Huisartsen). Pos-
sible candidates were selected from a computerized database
of the Center for Data and Information Management of Maas-
tricht University (MEMIC). This recruitment procedure was
subsequently backed up by advertisement in local newspa-
pers. Healthy controls were recruited by advertisements in
local newspapers.
Three groups of 16 subjects, ranging from 52 to 71 years of
age, participated in the present study. Groups were 16 indi-
viduals with insomnia who chronically used hypnotics
(“chronic users”: seven females and nine males), 16 individ-
uals with insomnia who did not or infrequently used hypnotics
(“infrequent users”: eight females and eight males), and 16
self-defined good sleepers, matched for age and driving expe-
rience (“controls”: seven females and nine males). Their mean
(±SD) ages were 62.6 (4.5) for the chronic users, 62.3 (6.2) for
the infrequent users, and 62.9 (4.3) for the controls.
Insomnia patients had to meet the inclusion criteria for
primary insomnia according to DSM-IV (Association AP
1994): (1) subjective complaints of insomnia, defined as
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difficulties initiating sleep (sleep latency >30 min) and/or
maintaining sleep (awakenings >30min); (2) duration of more
than 1 month; (3) the sleep disturbance causes clinically
significant distress or impairment; (4) insomnia does not occur
exclusively during the course of a mental disorder; and (5)
insomnia is not due to another medical or sleep disorder or
effects of medication or drug abuse.
Sleep complaints were measured using Dutch versions of
the Pittsburgh Sleep Quality Index (Buysse et al. 1989), the
Sleep Wake Experience List (van Diest et al. 1989), and the
general version of the Groningen Subjective Quality of Sleep
questionnaire (Mulder-Hajonides van der Meulen 1981). Ad-
ditionally, a daily journal and the specific version of the
Groningen Subjective Quality of Sleep questionnaire
(GSQS-spec) (Mulder-Hajonides van der Meulen 1981) were
completed upon arising each morning for 2 weeks providing
subjective estimates of sleep quality.
Insomnia patients were assigned to the “chronic users”
group when they used a benzodiazepine, zopiclone, or
zolpidem as sleeping medication for at least four nights per
week during the previous 3months ormore. Patients not using
hypnotics or using hypnotics less than or equal to 3 days per
week were assigned to the “infrequent users” group. Self-
defined good sleepers did not meet any of the criteria for
insomnia and did not use any hypnotics. Table 1 presents an
overview of the mean frequencies and durations of hypnotic
use per group, as well as the individual hypnotics and doses
used.
All participants had tomeet the following inclusion criteria:
possession of a valid driving license for at least 3 years;
average driving experience of at least 3,000 km per year over
the last 3 years; mentally and physically fit to drive; good
health based on a pre-study physical examination, medical
history, vital signs, electrocardiogram, blood biochemistry,
hematology, serology and urinalysis; body mass index be-
tween 19 and 30 kg/m2.
Exclusion criteria were history of drug or alcohol abuse;
presence of a significant medical, neurological, psychiatric
disorder, or sleep disorder other than insomnia; chronic use
of medication that affects driving performance, except hyp-
notics; drinking more than 6 cups of coffee per day; drinking
more than 21 alcohol containing beverages per week; and
smoking more than 10 cigarettes per day.
Participants were screened for major psychopathology by
use of the Symptom Checklist 90 Revised (Derogatis 1983),
the Beck Depression Inventory (Beck et al. 1961), the State-
Trait Anxiety Inventory (Spielberger et al. 1983), and the
Multidimensional Fatigue Inventory (Smets et al. 1995).
During participation, use of caffeine was prohibited from
8 h prior to arrival on test days, until discharge the next
morning. Alcohol intake was not allowed from 24 h prior to
each dosing until discharge. Smoking was prohibited from 1 h
prior to bedtime until discharge.
The study was conducted in accordance with the code of
ethics on human experimentation established by the World
Medical Association’s Declaration of Helsinki (1964) and
amended in Edinburgh (2000). The protocol was approved
by the medical ethics committee of Maastricht University and
University Hospital of Maastricht. Subjects were explained
the aims, methods, and potential hazards of the study and they
signed a written informed consent prior to any study-related
assessments.
Design and treatments
The study was conducted according to a 3×2 double-blind,
placebo controlled crossover design, with three groups (16
insomnia patients chronically using hypnotics, chronic users;
16 insomnia patients not or infrequently using hypnotics,
infrequent users; and 16 self-defined good sleepers, matched
for age and driving experience, controls) and two treatment
conditions. Treatments were single oral doses of zopiclone
Table 1 Demographics, sleep diary data, and overview of hypnotic use









Age (years) 62.6 (4.5) 62.3 (6.2) 62.9 (4.3)








11.9 (3.7) 12.4 (2.2) 2.5 (1.5)
Sleep Onset Latency (min) 43.6 (34.4) 60.8 (64.3) 14.0 (8.9)
Total Sleep Time (min) 381 (103) 306 (64) 448 (26)
Sleep Efficiency (%) 73.4 (14.1) 65.6 (14.2) 90.7 (7.3)
Number of users of hypnotics
(%)
16 (100 %) 10 (62.5 %) 0 (0 %)
Frequency of hypnotic use
(nights per week)
6.6 (1.0) 1.1 (0.8) 0
Duration of hypnotic use
(years)
7.1 (5.0) 7.8 (8.1) 0
Hypnotics and doses used (n)
Flurazepam 15 mg 1 0 –
Lorazepam 1 mg 0 1 –
Lormetazepam 0.5 mg 1 0 –
Lormetazepam 2 mg 1 0 –
Midazolam 7.5 mg 3 0 –
Nitrazepam 5 mg 1 1 –
Oxazepam 10 mg 1 0 –
Oxazepam 20 mg 1 0 –
Oxazepam 50 mg 1 0 –
Temazepam 10 mg 2 4 –
Temazepam 20 mg 1 1 –
Zopiclone 3.75 mg 2 0 –
Zopiclone 7.5 mg 1 3 –
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7.5 mg and placebo administered in identical looking capsules
and ingested immediately before retiring to bed at 2330 hours.
Treatments orders were balanced within groups (placebo–
zopiclone or vice versa). Washout periods between treatments
were at least 1 week.
In order to minimize withdrawal symptoms during the
placebo night, patients assigned to the chronic users group
were instructed to discontinue their hypnotic intake three
nights before each treatment period. Chronic users who ex-
pected difficulties during the three hypnotic-free nights were
provided escape medication, consisting of zolpidem at a max-
imum of one dose of 10 mg per night, to be used only in case
of intolerable withdrawal effects. Zolpidem 10 mg was select-
ed to limit variability in hypnotic drugs used and because it is
known to be free from residual effects when taken at bedtime
before 8 h of sleep (Vermeeren 2004).
A total of five patients from the chronic users group used
zolpidem as escape medication in the 3-day period before a
treatment night. Of those, three patients used escape medica-
tion in the night preceding the zopiclone condition, and four




Sleep during treatment nights was evaluated objectively by
polysomnography using montage including electroencephalo-
gram, electrooculogram, and electromyogram. Sleep stages
were visually assessed by qualified technicians according to
standardized criteria (Iber et al. 2007). Sleep continuity pa-
rameters derived after analysis are sleep onset latency (in
minute), wake after sleep onset (in minute), total sleep time
(in minute), sleep efficiency (in percent), and number of
awakenings. Sleep architecture parameters are percentages in
stage 1, stage 2, slow wave, and REM of the total sleep time.
Upon arising, subjects completed the GSQS-spec (Mulder-
Hajonides van der Meulen 1981). In addition, subjects esti-
mated sleep onset latency (in minute), total sleep time (in
minute), time awake before rising (in minute), and number
of awakenings.
Driving performance
Driving performance was assessed using two on-the-road
driving tests, a highway driving test, and a car following test.
The Highway Driving Test (O’Hanlon 1984) measures road
tracking performance that is mainly determined by the delay
lag between sensory information, execution of motor reaction,
and the vehicle’s dynamic response. In this test, subjects
operate a specially instrumented vehicle over a 100-km (61-
mi) primary highway circuit, accompanied by a licensed
driving instructor having access to dual controls. The subjects’
task is to maintain a constant speed of 95 km/h (58 mi/h) and a
steady lateral position between the delineated boundaries of
the slower traffic lane. The vehicle speed and lateral position
are continuously recorded. These signals are edited off line to
remove data recorded during overtaking maneuvers or distur-
bances caused by roadway or traffic situations. The remaining
data are then used to calculate means and standard deviations
of lateral position and speed. Standard deviation of lateral
position (SDLP in centimeters) is the primary outcome vari-
able. SDLP is a measure of road tracking error or “weaving.”
The test duration is approximately 1 h.
The Car-Following Test measures changes in controlled
information processing such as selective attention, stimulus
interpretation and decision making, and speed of an adaptive
motor response to events which are common in driving
(Brookhuis et al. 1994; Ramaekers and O’Hanlon 1994). In
the test, two vehicles travel in tandem over a two-lane, undi-
vided, secondary highway at 70 km/h (44 mi/h). An investi-
gator drives the leading car and the subject, in the second car,
is instructed to follow at a distance between 25 and 35 m.
Subjects are further instructed to constantly attend the leading
car since it may slow down or speed up at unpredictable times.
They are required to follow the leading car’s speed move-
ments, i.e., maintain the initial headway by matching the
velocity of the car to the other’s. During the test, the speed
of the leading car is automatically controlled by a modified
“cruise control” system. At the beginning, it is set to maintain
a constant speed of 70 km/h and, by activating a micropro-
cessor, the investigator can start sinusoidal speed changes
reaching amplitude of −10 km/h and returning to the starting
level within 50 s. The maneuver is repeated six times. The
leading car’s speed and signals indicating the beginning of the
maneuver are transmitted via telemetry to be recorded in the
following vehicle together with the following vehicle’s speed.
Phase-delay converted to a measure of the subject’s average
reaction time to the movement of the leading vehicle (RT, in
second) is taken as the primary dependent variable in this test.
A secondary measure in the Car Following Test is Gain. It
represents an amplification factor between the signals of the
two cars. This will be larger than 1 when the subject overreacts
to speed adaptations of the leading car. Test duration is ap-
proximately 25 min.
Cognitive and psychomotor performance
Cognitive and psychomotor performance was assessed by use
of a battery of laboratory tests for word learning, digit span,
critical tracking, divided attention, psychomotor vigilance,
and inhibitory control. Tests were previously proven to be
sensitive to daytime sleepiness or sedation due to use of
hypnotics (Vermeeren et al. 1995, 1998, 2002b; Verster et al.
2002; Leufkens et al. 2009; Leufkens and Vermeeren 2009).
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TheWord Learning Test, based on the Rey Auditory Verbal
Learning Test (Rey 1964), is a verbal memory test for the
assessment of immediate recall, delayed recall, and recogni-
tion performance. Fifteen monosyllabic nouns are presented
and at the end of the sequence the subject is asked to recall as
many words as possible. This procedure is repeated five times
and after a delay of at least 30min the subject is again required
to recall as many words as possible. At this trial, the nouns are
not presented. Finally, a sequence of 30monosyllabic nouns is
presented, containing 15 nouns from the original set and 15
new nouns in random order. The subject has to indicate
whether a noun originates from the old set or it is from a
new set of nouns.
The Psychomotor Vigilance Task (PVT, Dinges and Powell
1985) is based on a simple visual RT test. Subjects are re-
quired to respond to a visual stimulus presented at variable
interval (2,000 to 10,000ms) by pressing either the right or the
left button with the dominant hand. The visual stimulus is a
counter turning on and incrementing from 0 to 60 s at 1-ms
intervals. In response to the subject’s button press, the counter
display stops incrementing, allowing the subject 1 s to read the
RT before the counter restarts. If a response has not beenmade
in 60 s, the clock resets and the counter restarts. The test
duration is 10 min. The average reaction time and the number
of lapses (i.e., response times >500 ms) were used as the main
performance parameters.
The Critical Tracking Test measures the ability to control
an unstable signal in a tracking task. The signal deviates
horizontally from a midpoint and the subject has to compen-
sate this signal deviation by moving a joystick in opposite
direction The test includes five trials of which the lowest and
the highest score are discarded (Jex et al. 1966).
The Divided Attention Task measures the ability to divide
attention between two simultaneously performed tasks
(Moskowitz 1973). The first task is to perform a tracking test
at a fixed level of difficulty set at 50 % of the maximum score
obtained after extensive training of the Critical Tracking Test.
In the other task, the subject has to monitor 24 single digits
that are presented in the four corners of the screen. The digits
change asynchronously at 5-s intervals. The subjects are
instructed to remove their foot from a pedal as rapidly as
possible whenever the digit “2” appears. This signal occurs
twice at every location, in random order, at intervals of 5 to
25 s. Task duration is fixed at 12 min. The main performance
parameters are average tracking error (in millimeter) and
speed of target detection in the visual search task (in
millisecond).
In the Stop Signal Task, the concept of inhibitory control is
defined as the ability to stop a pending thought or action and to
begin another (Logan et al. 1984). The paradigm consists of
two concurrent tasks, i.e., a go task (primary task) and a stop
task (secondary task). The go signals (primary task stimuli)
are two letters (“X” or “O”) presented one at a time in the
center of a computer screen. Subjects are required to respond
to each letter as quickly as possible by pressing one of two
response buttons. Occasionally, a stop signal (secondary task
stimulus) occurs during the test. The stop signal consists of an
auditory cue, i.e., a 1,000-Hz tone that is presented for 100 ms.
The interval at which the stop signal is presented is dependent
on the subject’s own successful and unsuccessful inhibitions.
Subjects are required to withhold any response when a stop
signal is presented. By continuously monitoring the subject’s
response, the stop signal reaction time is calculated during the
task. Subjects are required to withhold any response when a
stop signal is presented.
Subjective evaluations
Subjective evaluations of driving quality, sedation, and mood
were assessed using a series of visual analogue scales
(100 mm). The driving instructors rated each subject’s driving
quality and apparent sedation at the conclusion of the High-
way Driving Test, using two 100-mm visual analogue scales.
Subjects rated the extent of influence of the drug on their
driving performance, prior to and upon completion of the
Highway Driving Test, using a 100-mm visual analogue scale.
In addition, subjects rated the degree of effort they had to put
in driving performance using the Rating Scale Mental Effort
(Zijlstra 1993). The scale is a visual analogue scale (150 mm)
with additional verbal labels.
The subjects were instructed to rate their subjective feelings
of alertness and sleepiness before the start of cognitive testing
using the Karolinska Sleepiness Scale with scores ranging
from 1 (extremely alert) to 9 (very sleepy, fighting sleep)
(Akerstedt and Gillberg 1990) and a 16-item mood scale
which provides three-factor analytically defined summary
scores for “alertness,” “contentedness,” and “calmness”
(Bond and Lader 1974).
Blood samples
Blood samples were taken at 9 1/2 h after ingestion of
zopiclone 7.5 mg to determine serum concentrations of hyp-
notics before driving. Samples were centrifuged after a
clotting period, and serum was frozen at −20 °C until analyses
for pharmacokinetic assessments.
Procedure
Subjects of all three groups were individually trained to per-
form the laboratory tests during two sessions of approximately
1.5 h in a previous study (Leufkens et al. 2014; Ramaekers
2011). In that study, they underwent two nights of sleep
evaluation at the research facilities of the university. Subjects
were therefore sufficiently familiarized with the testing facil-
ities and procedures.
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Treatment periods started in the evening of day 1,
when the subjects arrived at the site at approximately
2000 hours, and lasted until day 2, when they were
transported home after the driving test, at approximately
1145 hours. On arrival at the sleeping facility in each
treatment period, subjects’ eligibility was verified. They
were questioned about adverse events and use of med-
ication since their last visit. Hereafter, electrodes for
polysomnographic recording were attached.
Subjects ingested their medication and retired to bed
at 2330 hours. They were awakened at 0730 hours and
served a light standardized breakfast. At 0800 hours
(i.e., 8.5 h post dose), they filled out the subjective
rating scales for sleep, mood, and daytime sleepiness,
and started the laboratory tests. At approximately
0900 hours, a blood sample was taken. Subjects were
subsequently transported to the start of the highway
driving test. Before driving, they rated the anticipated
effect of the drug on their driving performance and
performed the highway driving test between 0930 and
1030 hours (i.e., 1000–1100 hours post-dose). Upon
completion, subjects were asked to rate the mental effort
it took to perform the driving test and to evaluate the
influence of the drug on their driving performance.
Next, subjects performed the car following test, after
which they returned to the testing facilities for removal
of the electrodes.
Statistical analysis
Sample size was based on a power calculation for detecting a
clinically relevant effect of 2.4 cm in the primary measure of
this study, the SDLP. This change corresponds to the effects of
alcohol on SDLP, while blood alcohol concentrations (BACs)
are 0.5 g/L as measured in a previous study (Louwerens et al.
1987). Given a test–retest reliability of SDLP of at least r=
0.70, a group of 16 subjects should permit detection of a mean
change in SDLP of 2.0 cm, with a power of at least 90 % and
an α risk of 0.05.
Overall effects were analyzed using a mixed model
analysis of variance with Group as between subject
factor with three levels (chronic users, infrequent users,
controls) and Treatment as within subjects factor with
two levels (zopiclone, placebo). Significant (p<0.05)
main effects or interactions were further analyzed using
three univariate comparisons between groups for each
treatment, and paired t tests between placebo and
zopiclone within each group. Finally, zopiclone–placebo
changes in SDLP were correlated with serum levels of
zopiclone for each group separately.
All statistical analyses were done by using the Statistical
Package for the Social Sciences (SPSS) statistical program
(version 15.0 for Windows; SPSS, Chicago, IL).
Results
Driving performance
Out of 96 driving tests, one was terminated before scheduled
completion because the driving instructor judged that it would
be unsafe to continue. The subject was a female insomnia
patient from the infrequent users group who had been admin-
istered zopiclone. Her SDLP score was calculated from the
data collected until termination of the ride.
Figure 1 presents mean ± SE SDLP values recorded after
placebo and zopiclone 7.5 mg for each group separately.
Analysis showed a highly significant overall treatment
effect on SDLP (F1,45=33.86, p<0.001). Zopiclone signifi-
cantly impaired driving in all groups. Compared to placebo,
the increase in SDLP was +1.6 cm (p=0.010) in the chronic
users group, +2.1 cm (p=0.020) in the infrequent users group
and +3.6 cm (p<0.001) in the healthy control group. t tests for
independent samples showed that the mean increase in SDLP
from placebo to zopiclone was significantly lower in the
chronic users group than the control group (p=0.045). There
was no difference between the infrequent users and controls
and between the two insomnia groups.
StandardDeviation of Speed (Table 1) showed a significant
main effect of treatment (F1,45=12.24, p=0.001) and a treat-
ment by group interaction (F2,45=3.42, p=0.041).
Overall, zopiclone significantly impaired subjects’ control
over speed variability. Paired t tests showed that zopiclone
significantly increased SDSP in the control group (p<0.004)
and the chronic users group (p=0.009), but not in the infre-
quent users group. There were no significant overall group
effects on SDSP.
There were no overall effects on any of the Car Following
Test parameters.
Subjective evaluations of driving performance
Mean ± SE scores of the subjective evaluations of driving
performance are presented in Table 2. The driving instructors
did not judge the subjects’ driving quality and appearance of
being sedated to be significantly different between zopiclone
and placebo in all groups.
Overall, subjects’ ratings of anticipated and experienced
driving quality were lower after zopiclone as compared to
placebo (anticipated: F1,44=6.14, p=0.017; experienced:
F1,44=5.79, p=0.020). Paired t tests showed that these differ-
ences reached significance within the control group, but not in
the patient groups. Healthy controls expected driving quality
to be worse after zopiclone administration (p=0.006) and they
confirmed this expectation after the driving test (p=0.013).
Changes in the patient groups were in the same direction, but
smaller. t tests for independent samples revealed that both
insomnia groups rated their driving quality in the placebo
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condition significantly lower than the control group (chronic
users: p=0.040; infrequent users: p=0.045).
Overall, subjects’ perceived mental effort to perform the
driving test was increased after zopiclone as compared to
placebo (F1,45=16.15, p<0.001). Paired t tests showed that
this difference reached significance within the control group
(p=0.009) and the infrequent users group (p=0.008), but not
in the chronic users group. Differences between groups were
not significant.
Subjective evaluations of sleepiness and feelings
Mean ± SE scores of the subjective evaluations of sleepiness
and feelings are presented in Table 2. Subjects’ ratings of
sleepiness as measured by the Karolinska Sleepiness Scale
were significantly different between groups (F2,44=5.28, p=
0.009), but not between treatments. The chronic users group
felt more sleepy than the healthy controls after placebo (p=
0.003) and after zopiclone (p=0.023) administration.
Subjective feelings of alertness and contentedness showed
a significant treatment by group interaction (F2,45=4.81, p=
0.013 and F2,45=3.25, p=0.048, respectively). In the placebo
condition, the insomnia groups felt significantly less alert than
the control group. This difference was significant for the
chronic users group (p=0.011). Use of zopiclone increased
next day alertness in the chronic users (p=0.029), whereas it
impaired alertness in the healthy controls (p=0.040). For
feelings of contentedness, further analyses did not reveal
differences between treatments and groups.
There were no overall main effects for subjective feelings
of calmness.
Cognitive and psychomotor assessment
Table 3 summarizes the mean ± SE scores of the cognitive
performance tests.
Overall, zopiclone impaired all parameters of theWord Learn-
ing Test, i.e., immediate recall (F1,45=9.78, p=0.003), delayed
recall (F1,45=5.49, p=0.024), recognition score (F1,45=6.48, p=
0.014), and recognition reaction time (F1,45=8.50, p=0.006).
Paired t tests revealed that these effects did not reach significance
in each group separately, except for the effect on immediate recall
in the infrequent users group (p=0.039), and the effects on the
recognition score in the control group (p=0.045). t tests for
independent samples revealed that the chronic users scored
significantly worse than the healthy controls on the immediate
recall score in the placebo condition (p=0.020). Other significant
group differences were not found.
Performance in the Psychomotor Vigilance Task did not
show significant overall differences between treatments and
groups.
Overall, zopiclone affected psychomotor performance in
the Critical Tracking Task (F1,44=8.15, p=0.007). Analysis
for groups separately did not reveal significant treatment
effects, however.
In the Divided Attention Task, there was an overall signif-
icant impairment by zopiclone in both the tracking subtask
(F1,44=16.49, p<0.001) and the detection subtask (F1,44=
4.81, p=0.034). Tracking, as reflected by the average error,
was significantly worse after zopiclone administration in both
insomnia groups (chronic users: p=0.024; infrequent users:
p=0.008), but not in the control group. Detection, as reflected
by reaction time, was significantly impaired following





Fig. 1 Mean (±SE) SDLP for
each group separately (*p<0.05,
significant drug effect)
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A significant overall treatment effect was found on the num-
ber of hits (F1,43=6.31, p=0.016) and the go reaction time
(F1,43=12.63, p<0.001) in the Stop Signal Task. For the number
of hits, paired t tests revealed that this effect did not reach
significance in each group separately, however. Paired t tests
did show that the go reaction time was significantly slower after
zopiclone administration in the infrequent users (p=0.026) and
the controls (p=0.033). Stop reaction time showed a significant
main effect of treatment (F1,43=15.84, p=0.001), a significant
overall group difference (F2,43=4.58, p=0.016) and a treatment
by group interaction (F2,43=3.67, p=0.034).
Overall, zopiclone significantly slowed subjects’ response
to a stop signal. Paired t tests showed that zopiclone signifi-
cantly increased stop reaction time in the infrequent users
group (p=0.046) and the control group (p=0.007), but not in
the chronic users group.
Overall analysis for group differences revealed a significant
effect following zopiclone administration (F2,44=5.27, p=
0.009), but not following placebo administration. Post hoc
analysis showed that the chronic users had significantly less
problems with responding to a stop signal after zopiclone than
the controls had (p=0.002).
Table 2 Mean (±SE) scores of driving tests and subjective evaluations for each condition and group separately
Variable Group Statistics (p values)
Treatment Chronic users Infrequent users Controls Treatment × group Treatment Group
Highway Driving Test
SDLP (cm) Placebo 19.7 (1.0) 18.2 (0.9) 17.8 (0.6) NS <0.001 NS
Zopiclone 21.3 (1.2)a 20.3 (1.0)a 21.4 (1.0)a
SDSP (km/h) Placebo 2.2 (0.1) 2.3 (0.2) 2.1 (0.1) 0.041 0.001 NS
Zopiclone 2.5 (0.2)a 2.4 (0.1) 2.5 (0.4)a
Car following test
Reaction time (s) Placebo 4.3 (0.5) 4.7 (0.4) 4.2 (0.6) NS NS NS
Zopiclone 4.5 (0.3) 3.8 (0.5) 4.4 (0.6)
Gain Placebo 1.2 (0.05) 1.1 (0.03) 1.2 (0.06) NS NS NS
Zopiclone 1.2 (0.06) 1.2 (0.07) 1.1 (0.03)
Subjective evaluations by driving instructors
Driving quality Placebo 58.4 (5.8) 58.8 (4.6) 59.2 (5.0) NS NS NS
Zopiclone 58.6 (4.7) 61.1 (4.5) 55.8 (3.8)
Apparent sedation Placebo 18.9 (5.4) 15.1 (5.0) 18.4 (6.0) NS NS NS
Zopiclone 23.4 (4.3) 21.8 (3.2) 21.8 (4.4)
Subjective evaluations by participants
Anticipated driving quality Placebo 71.7 (5.6) 73.6 (4.8) 86.2 (3.5) NS 0.017 NS
Zopiclone 67.6 (6.2) 71.7 (5.9) 66.4 (5.5)a
Experienced driving quality Placebo 67.9 (4.9) 65.0 (4.5) 78.3 (4.3) NS 0.020 NS
Zopiclone 60.8 (5.4) 62.4 (6.1) 66.8 (5.8)a
Mental effort Placebo 31.4 (5.3) 35.4 (5.4) 24.8 (4.7) NS <0.001 NS
Zopiclone 45.1 (8.9) 53.3 (7.9)a 45.1 (6.8)a
Karolinska Sleepiness Scale Placebo 5.1 (0.4)b 4.4 (0.5) 3.5 (0.3) NS NS 0.009
Zopiclone 5.1 (0.4)b 4.6 (0.4) 3.7 (0.3)
Alertness Placebo 58.8 (4.5)b 64.9 (4.1) 73.9 (3.4) 0.013 NS NS
Zopiclone 69.2 (3.9)a 65.8 (2.8) 66.2 (4.7)a
Contentedness Placebo 68.3 (3.8) 72.0 (3.4) 76.5 (4.2) 0.048 NS NS
Zopiclone 75.3 (3.5) 73.7 (3.7) 71.3 (4.5)
Calmness Placebo 72.6 (3.9) 75.9 (3.9) 75.2 (3.7) NS NS NS
Zopiclone 71.2 (3.5) 74.1 (4.0) 76.0 (3.6)
NS no significant effect
a Significantly different from placebo within group (p<0.05)
b Significantly different from control group (p<0.05)
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Sleep quality
Subjective evaluation
Table 4 summarizes the mean ± SE scores of both the subjec-
tive and objective sleep parameters for each group separately
after administration of placebo and zopiclone.
Significant overall main effects of treatment and group
were found for all parameters (number of complaints: F1,45=
49.34, p<0.001; sleep onset time: F1,45=14.05, p=0.001;
number of awakenings: F1,45=33.56, p<0.001; total sleep
time: F1,44=52.29, p<0.001). In addition, significant interac-
tions showed that the effect of zopiclone differed between
groups in number of complaints (F2,45=4.18, p=0.022), sleep
onset time (F2,45=3.24, p=0.049), and total sleep time (F2,44=
4.90, p=0.012). Paired t tests of treatment effect for each
group separately showed that in both insomnia groups number
of sleep complaints was significantly reduced (both groups:
p<0.001) and total sleep time was significantly increased
(chronic users: p<0.001; infrequent users: p=0.001) after
zopiclone administration. Number of awakenings was signif-
icantly reduced after zopiclone in all groups (chronic users:
p=0.022; infrequent users: p<0.001; controls: p=0.008).
Sleep onset time was significantly diminished after zopiclone
in the chronic users group only (p=0.014).
Significant differences between chronic users and controls
were found in number of complaints (p<0.001), sleep onset
time (p=0.006), and total sleep time (p<0.001) after placebo.
Table 3 Mean (±SE) scores of cognitive performance tests for each condition and group separately
Variable Group Statistics (p values)
Treatment Chronic users Infrequent users Controls Treatment × group Treatment Group
Word Learning Test
Immediate recall score Placebo 39.5 (1.9) 43.6 (2.2) 46.2 (1.9) NS 0.003 NS
Zopiclone 35.4 (2.9) 39.1 (2.7)a 41.6 (2.5)
Delayed recall Placebo 5.3 (0.7) 6.8 (0.9) 7.3 (0.8) NS 0.024 NS
Zopiclone 4.8 (0.8) 5.8 (0.8) 5.4 (0.7)
Recognition score Placebo 25.4 (1.1) 25.0 (1.3) 25.5 (1.3) NS 0.014 NS
Zopiclone 24.4 (0.8) 23.4 (1.4) 23.5 (1.5)a
Recognition reaction time (ms) Placebo 848 (32) 785 (36) 851 (33) NS 0.006 NS
Zopiclone 889 (39) 863 (40) 893 (34)
Psychomotor Vigilance Task
Average reaction time (ms) Placebo 290 (13) 290 (15) 281 (8) NS NS NS
Zopiclone 288 (12) 303 (16) 297 (11)
Lapses (>500 ms) Placebo 3.1 (1.0) 1.7 (0.4) 2.1 (0.6) NS NS NS
Zopiclone 2.6 (0.8) 3.1 (1.0) 2.6 (0.6)
Critical Tracking Task
Average lambda (rad/s) Placebo 3.1 (0.2) 2.9 (0.2) 2.8 (0.2) NS 0.007 NS
Zopiclone 2.9 (0.2) 2.7 (0.2) 2.7 (0.1)
Divided Attention Task
Average error (mm) Placebo 16.5 (1.5) 18.4 (1.1) 19.8 (1.3) NS <0.001 NS
Zopiclone 18.9 (1.2)a 20.5 (1.3)a 21.4 (1.1)
Reaction time (ms) Placebo 2,052 (87) 1,971 (75) 1,941 (81) NS 0.034 NS
Zopiclone 2,038 (65) 2,086 (71)a 2,140 (93)
Stop Signal Task
Hits (#) Placebo 241 (3) 246 (1) 247 (1) NS 0.016 NS
Zopiclone 240 (3) 245 (1) 245 (2)
Go reaction time (ms) Placebo 437 (19) 432 (19) 438 (13) NS 0.001 NS
Zopiclone 442 (18) 452 (20)a 459 (15)a
Stop reaction time (ms) Placebo 181 (7) 184 (8) 202 (10) .034 <0.001 0.016
Zopiclone 184 (9)b 197 (8)a 229 (9)a
NS = no significant effect
a Significantly different from placebo within group (p<0.05)
b Significantly different from control group (p<0.05)
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Following zopiclone administration, chronic users reported
significantly more sleep complaints (p=0.007), shorter total
sleep time (p=0.001), and more awakenings (p=0.015) than
controls.
Comparisons between the infrequent users and the controls
revealed that there were significant differences in number of
complaints (p=0.001), total sleep time (p=0.001), and number
of awakenings (p=0.027) after administration of placebo.
Differences between the groups disappeared after zopiclone
administration.
Comparisons between the insomnia groups showed that the
chronic users had a significantly longer sleep onset time (p=
0.006) and a significantly shorter total sleep time (p=0.001)
than the infrequent users in the placebo condition. There were
no differences between the insomnia groups after zopiclone
administration.
Polysomnographic parameters
Significant overall main treatment effects were found in all
polysomnographic parameters for sleep continuity (sleep on-
set time: F1,42=4.97, p=0.031; wake after sleep onset: F1,41=
18.71, p<0.001; number of awakenings: F1,42=9.36, p=
0.004; total sleep time: F1,42=23.30, p<0.001; sleep efficien-
cy: F1,41=23.26, p<0.001). Paired t tests showed that follow-
ing zopiclone administration all groups slept significantly
longer (chronic users: p=0.033; infrequent users: p=0.014;
controls: p=0.006) and improved their sleep efficiency
Table 4 Mean (±SE) scores of subjective and objective sleep quality
Variable Group Statistics (p values)
Treatment Chronic users Infrequent users Controls Treatment × group Treatment Group
Subjective
Groningen Sleep Quality Scale Placebo 10.8 (0.8)a 8.9 (0.9)a 4.2 (1.0) 0.022 <0.001 <0.001
Zopiclone 5.3 (1.0)a, b 3.3 (0.6)b 2.4 (0.5)
Sleep onset time (min) Placebo 114 (22)a, c 53 (11) 36 (8) 0.049 0.001 <0.001
Zopiclone 44 (11)b 27 (4) 24 (4)
Awakenings (#) Placebo 3.5 (0.6) 3.8 (0.6)a 2.0 (0.4) NS <0.001 0.027
Zopiclone 1.9 (0.4)a, b 1.4 (0.4)b 0.7 (0.2)b
Total sleep time (min) Placebo 241 (21)a 291 (23)a 385 (13) 0.012 <0.001 <0.001
Zopiclone 355 (18)a, b, c 403 (12)b 419 (8)b
Polysomnographic parameters
Sleep onset time (min) Placebo 42.8 (7.6)c 21.2 (4.3) 25.9 (4.5) NS 0.031 0.008
Zopiclone 31.3 (4.8)c 16.6 (2.6) 22.5 (2.6)
Wake after sleep onset (min) Placebo 94.1 (11.4) 73.5 (9.2) 73.6 (13.2) NS <0.001 0.029
Zopiclone 78.2 (12.6)a, c 48.4 (5.2)b 35.9 (4.5)b
Awakenings (#) Placebo 8.7 (1.2) 7.6 (0.8) 7.3 (1.1) NS 0.004 NS
Zopiclone 7.5 (1.0) 5.9 (0.8) 4.4 (0.8)b
Total sleep time (min) Placebo 343 (15) 386 (11) 381 (13) NS <0.001 0.002
Zopiclone 372 (14)a, b, c 414 (6)b 423 (5)b
Sleep efficiency (%) Placebo 71.5 (3.1) 80.4 (2.4) 79.6 (2.7) NS <0.001 0.002
Zopiclone 77.3 (2.9)a, b, c 86.9 (1.0)b 88.6 (0.7)b
Stage 1 sleep (% of total sleep time) Placebo 7.9 (0.9) 6.7 (0.8) 7.2 (1.1) NS 0.007 NS
Zopiclone 7.5 (1.0) 4.8 (0.6)b 5.1 (0.8)b
Stage 2 sleep (% of total sleep time) Placebo 55.9 (2.1) 51.5 (1.6) 53.2 (2.3) NS 0.009 NS
Zopiclone 59.9 (2.2) 54.1 (2.0) 55.9 (2.2)
Stage SWS sleep (% of total sleep time) Placebo 15.1 (2.3) 20.6 (1.9) 20.7 (2.2) NS 0.001 NS
Zopiclone 18.5 (2.4) 24.4 (2.1)b 21.9 (2.2)
Stage REM sleep (% of total sleep time) Placebo 20.9 (1.2) 21.1 (1.3) 18.9 (1.0) 0.027 <0.001 NS
Zopiclone 14.1 (0.8)b 16.8 (1.3)b 17.0 (1.0)
NS no significant effect
a Significantly different from control group (p<0.05)
b Significantly different from placebo within group (p<0.05)
c Significantly different from infrequent users group (p<0.05)
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(chronic users: p=0.034; infrequent users: p=0.012; controls:
p=0.009). Furthermore after zopiclone, the infrequent users
and controls had significantly less time awake after sleep onset
(p=0.016 and p=0.017, respectively). Lastly, the controls had
significantly fewer awakenings after zopiclone administration
as compared to placebo (p=0.027).
Except in the number of awakenings, significant
overall group effects were found in all objective evalu-
ations (sleep onset time: F2,42=5.47, p=0.008; wake
after sleep onset: F2,41=3.86, p=0.029; total sleep time:
F2,42=7.11, p=0.002; sleep efficiency: F2,41=7.61, p=
0.002). Following zopiclone administration and com-
pared to both the controls and infrequent users, the
chronic users had a significantly longer wake after sleep
onset time (p=0.001 and p=0.033, respectively), signif-
icantly less total sleep time (p=0.001 and p=0.004,
respectively), and significantly worse sleep efficiency
(p<0.001 and p=0.001, respectively). Sleep onset time
appeared to be significantly longer for the chronic users
as compared to the infrequent users after both placebo
(p=0.029) and zopiclone administration (p=0.010). No
differences between infrequent users and controls were
found on any of the parameters for sleep continuity
after placebo or zopiclone administration.
Overall main effects of treatment were also found in
all parameters for sleep architecture (percentage of stage
1 sleep: F1,42=8.13, p=0.007; percentage of stage 2
sleep: F1,42=7.40, p=0.009; percentage of slow wave
sleep: F1,42=11.57, p=0.001; percentage of REM sleep:
F1,42=37.10, p<0.001). In the infrequent users, stage 1
sleep and REM sleep were significantly reduced after
zopiclone administration (p=0.028 and p=0.001, respec-
tively) and slow wave sleep was significantly increased
(p=0.001). Zopiclone also significantly decreased the
percentage of stage 1 sleep in the controls (p=0.042)
and REM sleep in the chronic users (p<0.001).
Overall main group differences were not found on any of
the parameters. A significant treatment by group interaction
was shown in the percentage of REM sleep. Yet, further
analysis did not reveal any group differences.
Serum concentrations
Mean (±SE) serum concentrations for zopiclone were
9.9 (1.0)ng/mL in the chronic users group, 11.3 (1.2)
ng/mL in the infrequent users group, and 10.7 (0.7)ng/
mL in the controls group. Overall group analysis re-
vealed no significant differences between the three
groups.
Correlations between change in SDLP from placebo to
zopiclone and serum concentrations were 0.06 (n.s.) for the
chronic users, 0.48 (n.s.) for the infrequent users, and 0.54
(p<0.05) for the controls.
Discussion
Results of the present study show that a single oral dose of
zopiclone 7.5 mg significantly impairs on-the-road driving
performance in insomnia patients who chronically use hyp-
notics, in insomnia patients who not or infrequently use hyp-
notics, and in healthy, good sleepers at 10 to 11 h after bedtime
administration. The impairing effect of zopiclone on driving,
as reflected by the rise in SDLP compared with placebo, was
significantly different between the chronic users and the
healthy controls. As a result, interpretation of the severity of
the effects differs between groups. The effect found in the
chronic users group (+1.6 cm) is on average of lesser magni-
tude than that produced by alcohol in a previous study while
subjects drove with BAC of 0.5 mg/mL (+2.4 cm)
(Louwerens et al. 1987), which is the legal limit for driving
a car in most countries. In contrast, the increase of 3.6 cm in
SDLP from placebo after zopiclone 7.5 mg administration in
the healthy control group is above this effect of alcohol.
Zopiclone produced an effect of +2.1 cm in the infrequent
users group, which was slightly less than that of alcohol while
BACs are 0.5 mg/mL. However, there was no statistical
difference in the effect of zopiclone between the infrequent
users and the controls.
The significantly decreased magnitude of effect of
zopiclone 7.5 mg on driving performance in the chronic users
as compared to the healthy controls suggests that residual
effects are attenuated by chronic use of hypnotics. This may
be explained by the development of tolerance towards the
impairing effects of zopiclone even for those patients using
hypnotics other than zopiclone as cross-tolerance from ben-
zodiazepines to zopiclone has been shown previously (Lader
1997). This implicates that results from studies conducted
with healthy volunteers appear to give an overestimation of
the actual effects in insomnia patients chronically using hyp-
notics. It should be mentioned, however, that SDLP scores
following zopiclone administration were still significantly
increased in the chronic users group, indicating that residual
effects do not completely disappear.
An alternative explanation for the decreased effect of
zopiclone on driving in chronic users may be the occurrence
of withdrawal symptoms in the placebo condition. Mean
SDLP scores after zopiclone were comparable between the
three groups. After placebo, however, mean SDLP in the
chronic users group was elevated compared with the infre-
quent users and healthy controls, although the difference did
not reach statistical significance. This indicates worse perfor-
mance and suggests that withdrawal symptoms may have
been present in the chronic users despite discontinuation of
their own hypnotic intake 3 days before each treatment period.
The patients may have experienced discomfort from the
hypnotic-free night which may have impaired their driving
performance. So, the difference in SDLP scores between
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placebo and zopiclone in the chronic users may be relatively
small due to their bad performance in the placebo condition.
Yet, according to polysomnographic analyses, sleep in the
chronic users appeared not to be significantly affected by
possible withdrawal effects during the placebo night. Besides
a significant difference of 20 min in sleep onset as compared
to the infrequent users, the sleep profile of the chronic users
was comparable with that of the other two groups. The only
support for reduced ability to perform in the chronic users due
to withdrawal symptoms in the placebo condition may be the
decreased feelings of alertness and increased feelings of sleep-
iness as compared to the controls following placebo adminis-
tration. Even more, the chronic users reported feeling signif-
icantly more alert after the zopiclone night, whereas the con-
trols felt the exact opposite. This may suggest that the chronic
users experienced more discomfort after the placebo night
than after the zopiclone night and may have influenced their
driving performance. After all, this was their fourth hypnotic-
free night in succession possibly causing physical problems
(Pétursson 1994).
The magnitude of residual effects of zopiclone 7.5 mg
found in the infrequent users group is in line with previous
studies conducted in healthy younger drivers (Vermeeren et al.
1998, 2002b; Leufkens et al. 2009). In those studies, the mean
increase in SDLP from placebo after zopiclone administration
ranged from +2.5 to +4.9 cm. This suggests that the residual
effects of hypnotics found in healthy volunteers can validly
predict the effects in older patients suffering from insomnia.
The impairing effects on driving after zopiclone appeared
not to be noticed by the insomnia patients. Prior to the start of
the driving test, they did not expect to drive differently after
administration of zopiclone than after placebo. In addition,
after completion of the test, they did not rate their driving
quality differently between zopiclone and placebo. In contrast,
the healthy controls anticipated their driving quality to be
significantly worse after zopiclone. Their expectations were
confirmed by their performance as they evaluated their driving
quality after the test significantly lower after zopiclone admin-
istration as compared with placebo.
Whereas the residual adverse effects of zopiclone remained
undetected by the insomnia patients according to their subjec-
tive evaluations, opposite results were found for the evalua-
tions of its therapeutic effects. Both insomnia groups reported
significantly improved subjective sleep quality on most pa-
rameters after zopiclone administration as compared with
placebo. The healthy controls, however, appeared to benefit
considerably less from the sleep-inducing properties of
zopiclone. According the objective measures of sleep, there
were virtually no differences in sleep quality between the
groups, however. Still, the chronic users group felt significant-
ly more alert the morning after an evening dose of zopiclone
than after placebo. The infrequent users did not report a
difference in alertness, whereas the healthy controls reported
feeling significantly less alert after zopiclone than after
placebo.
The lack of awareness of residual sedative effects of
zopiclone 7.5 mg may cause insomnia patients to belief that
car driving is safe the morning after evening administration.
Even more, these beliefs may be strengthened by the experi-
enced improvement of subjective sleep quality. These results
stress, however, the importance of general physicians to warn
their patients about the impairing effects of zopiclone 7.5 mg
on driving performance.
In contrast to the significant effects of zopiclone on the
highway driving test, no impairment was found on the car
following test. It appears that monotonous tasks, such as the
highway driving test, are more sensitive to hypnotic-induced
sedation than more complex, rule-based tasks, such as the car
following test. A similar discrepancy of results has been found
in a study investigating the effects of sleep deprivation on
driving (Bosker et al. 2012). It is explained in that study that
the car following test consists of stimuli generating interest
and effort and, consequently, participants are able to compen-
sate for their sleepiness. It may well be the case that a similar
mechanismwas present in the participants of the current study.
The impairing effects of zopiclone on highway driving
performance could not be completely corroborated by the
results of the cognitive performance tests. Although there
were overall significant differences between placebo and
zopiclone on a majority of the parameters, in about only half
of the cases impairing effects of zopiclone were found in one
or two specific groups. For instance, zopiclone only impaired
immediate recall in the infrequent users group and recognition
performance in the healthy controls. Evident impairing resid-
ual effects of zopiclone 7.5 mg on verbal learning have been
found recently, however, in both healthy older and younger
subjects (Leufkens et al. 2009; Leufkens and Vermeeren
2009). Average scores of the three groups in the present study
following placebo administration appeared to be slightly low-
er already than the average scores of healthy older subjects in
the previous study (Leufkens and Vermeeren 2009). This may
suggest that scores were close to a minimum, showing possi-
ble floor effects.
Performance on the psychomotor vigilance task was not
different between placebo and zopiclone administration. Al-
though there is ample evidence that the PVT is highly sensi-
tive to the effects of sleep deprivation (Lim and Dinges 2008),
there seem to be almost no studies assessing effects of sedat-
ing drugs on this test. To our knowledge, the sedative residual
effects of zopiclone 7.5 mg have not yet been investigated
with use of this task. There are two recent studies showing
significant effects of blood alcohol concentrations of 0.03 and
0.05 mg/mL on PVT performance in healthy subjects
(Howard et al. 2007; Jongen et al. 2014). This suggests that
the task should have been sufficiently sensitive to detect the
residual effects zopiclone, which were comparable in
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magnitude to those of blood alcohol concentrations of
0.05 mg/mL as measured by SDLP. The failure to find an
effect on the PVT therefore indicates that performance on this
test is less sensitive to residual effects of GABAergic hypnotic
drugs than acute effects of alcohol.
There are also limitations to this study. Sleep was not
measured during the period that the chronic users were re-
quested to refrain from taken their own hypnotics. A possible
accumulation of sleep loss due to rebound insomnia caused by
withdrawal from hypnotic use cannot be verified therefore. An
indirect indication that withdrawal symptoms may have been
mild is the number of chronic users taking zolpidem 10 mg as
escape medication in the 3-day period before a treatment
condition. Only five participants needed escape medication,
but not on all days and 11 participants did not take any
medication. Still, as has been reviewed extensively, rebound
insomnia is very likely to occur after discontinuation of chron-
ic use of hypnotics (Gillin et al. 1989; Kales et al. 1990).
Another limitation of this study may be that the effects on
driving have only been investigated after a single dose of
zopiclone. A study in which administration of a hypnotic
occurred, for example, for at least a week could have better
been able to show the effects of the development of tolerance.
It may be expected in that case that the difference in effect
between day 1 of dosing and day 8 of dosing would be smaller
in chronic users than in infrequent users and healthy controls.
A placebo condition of 1 week, however, is likely to be too
long for chronic users creating a practical problem for such
studies.
To summarize, results of the present study indicate that
driving performance is mildly impaired in insomnia patients
after evening administration of zopiclone 7.5 mg at least until
11 h after intake. Chronic use of hypnotics seems to attenuate
the severity of effects of zopiclone 7.5 mg. Nevertheless, this
reduction does not result in an absence of impairing effects in
insomnia patients chronically using hypnotics. The magnitude
of effects found in the infrequent users group was slightly
smaller than found in previous studies investigating residual
effects of zopiclone 7.5 mg in healthy, younger volunteers.
This suggests that investigating residual effects of hypnotics
in healthy volunteers may yield a minor overestimation of the
actual effects in insomnia patients who start using hypnotics.
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